NCT01695590 - Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

September 30, 2014

Conditions

Multiple Myeloma

Interventions

DRUG

PRLX 93936

PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered

Trial Locations (6)

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

27710

RECRUITING

Duke University Medical Center, Durham

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

45267

RECRUITING

University of Cincinnati, Cincinnati

02111

WITHDRAWN

Tufts Medical Center, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston